Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
This grant supports exploratory or developmental bioengineering research that demonstrates feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, or accessibility. It funds work addressing problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. The program is offered by the National Cancer Institute.
Key facts
Update history